Quantcast
Last updated on April 24, 2014 at 11:48 EDT

Latest Escitalopram Stories

2008-06-18 09:01:19

WALTHAM, Mass., June 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Lexapro is the leading single agent used in anxiety therapy with 11.7 percent and 14.9 percent of first- and second-line patient share, respectively. According to surveyed psychiatrists and primary care physicians (PCPs), Lexapro is distinguished by its superior safety and tolerability profile; physicians specifically...

2008-06-17 09:01:13

Lupin Pharmaceuticals has received tentative approval from the FDA for the company's abbreviated new drug application for Escitalopram oxalate tablets 10mg and 20mg. Lupin's Escitalopram tablets are the AB-rated generic equivalent of Forest Laboratories's Lexapro tablets, indicated for the treatment of major depressive disorder. The product will be introduced in the market through Lupin's network of national wholesalers and drug stores post patent expiry in March 2012. This is expected to...

2008-06-16 12:01:04

BALTIMORE, June 16 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Escitalopram Oxalate Tablets 10 mg and 20 mg from the U.S. Food and Drug Administration (USFDA). Lupin's Escitalopram tablets are the AB-rated generic equivalent of Forest Laboratories' Lexapro(R) tablets, indicated for the treatment of major depressive disorder. The brand product had annual sales of...

3471cecb79734a5f5ae940ca31dde76c1
2007-04-17 17:20:00

CHICAGO -- Authors of a new comprehensive analysis of antidepressants for children and teenagers say the benefits of treatment trump the small risk of increasing some patients' chances of having suicidal thoughts and behaviors. The risk they found is lower than the one the Food and Drug Administration identified in 2004, the year the agency warned the public about the drugs' risks in children. After the warning, U.S. youth suicides increased and some mental health experts said reluctance to...

e07e5728bcedffc9b20eded882c53a191
2007-02-16 18:00:00

By MARYCLAIRE DALE PHILADELPHIA - The oldest son of Philadelphia Eagles coach Andy Reid has entered a drug-treatment program amid charges he injured a woman in a traffic accident while under the influence of heroin. Garrett Reid, 23, a community-college student who lives at his parents' home in Villanova, was arraigned Friday on the misdemeanor assault, drug possession and other charges. Andy Reid was not in court, but planned to accompany his son back to the out-of-state treatment facility...

2006-05-24 13:07:30

NEW YORK (Reuters Health) - Among men with major depression, treatment with Cymbalta is associated with less worsening of sexual function than is treatment with Lexapro, investigators reported this week at the American Psychiatric Association 2006 annual meeting in Toronto. "When we take surveys of patients who take their antidepressants only intermittently or discontinue them altogether, about two-thirds of patients will say it is because of side effects, of which the most common...

2006-05-24 12:43:56

NEW YORK (Reuters Health) - Among men with major depression, treatment with Cymbalta is associated with less worsening of sexual function than is treatment with Lexapro, investigators reported this week at the American Psychiatric Association 2006 annual meeting in Toronto. "When we take surveys of patients who take their antidepressants only intermittently or discontinue them altogether, about two-thirds of patients will say it is because of side effects, of which the most common...

2006-05-24 09:45:23

NEW YORK (Reuters Health) - Among men with depression, treatment with the antidepressant Cymbalta (duloxetine) does not worsen sexual functioning, as is common for most antidepressants, investigators reported this week at the American Psychiatric Association 2006 annual meeting in Toronto. "When we take surveys of patients who take their antidepressants only intermittently or discontinue them altogether, about two-thirds of patients will say it is because of side effects, of which...

2005-11-14 10:57:52

COPENHAGEN (Reuters) - Danish pharmaceutical group Lundbeck said on Monday that two Phase III studies had shown its anti-depressant Cipralex to be effective in treatment of obsessive-compulsive disorder (OCD). Cirpralex, sold in the United States as Lexapro by Forest Laboratories, is approved for the treatment of depression, panic disorder, social anxiety disorder and generalized anxiety disorder. Lundbeck will file for approval of the drug's use for OCD in the European Union in the...